Introduction
Hsp90 plays an important role in the conformational maturation and stabilization of several important proteins (known as clients) and is required for the protein refolding after exposure to various cell stresses (Pearl and Prodromou, 2001; Neckers, 2002) . Geldanamycin (GM), an ansamycin antibiotic, binds tightly to the ATP-binding pocket of Hsp90 and specifically disrupts its function, and therefore leads to the proteasome-dependent degradation of various client proteins (Prodromou et al., 1997) . They include steroid hormone receptors, Raf-1, Bcr-Abl, Akt and so on, which are important components of the signaling pathways of cell proliferation and survival (Nimmanapalli et al., 2001; Neckers, 2002; Workman, 2004) . Because these pathways are constitutively activated in many tumor cells, GM is expected to have a potent antitumor activity (Gorre et al., 2002; Minami et al., 2002; Bisht et al., 2003) . GM and its less toxic derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) have been reported to inhibit tumor cell growth by inducing apoptosis and, in certain cell types, differentiation (Mu¨nster et al., 2001; Jones et al., 2004; Mitsiades et al., 2006) . GM is reported to enhance tumor cell sensitivity to various cytotoxic agents and ionizing radiation through the inhibition of nuclear factor (NF)-kB activation and its downstream survival signals (Lewis et al., 2000; Broemer et al., 2004) .
The most fundamental mechanism of G 2 checkpoint is Cdc2 inactivation by negative phosphorylation. Chk1 plays the central role in DNA damage-induced G 2 arrest by maintaining Cdc25C in the phosphorylated inactive form, which suppresses Cdc2 activation (Elledge, 1996; Peng et al., 1997; Sanchez et al., 1997; Weinert, 1997; Bulavin et al., 2003) . Caffeine has been shown to abrogate DNA damage-induced G 2 arrest by inhibiting Ataxia telangiectasia mutated (ATM) and ATM-related (ATR) kinases, which situated upstream of Chk1 in the DNA damage checkpoint pathway (Fan et al., 1995; Powell et al., 1995; Russell et al., 1995; Yao et al., 1996; Sarkaria et al., 1999) . UCN-01 is known to sensitize tumor cells without functional p53 to DNA damaging agents by abrogating G 2 arrest through the direct inhibition of Chk1 (Graves et al., 2000; Zhao et al., 2002; Tse and Schwartz, 2004) . Furthermore, several agents inactivating Chk1 are reported to abrogate G 2 arrest and simultaneously sensitize tumor cells to DNAdamaging agents (Kohn et al., 2003; Kawabe, 2004) . Recently, Chk1 has been identified as an Hsp90 client and 17-AAG-mediated depletion of Chk1 has been shown to sensitize tumor cells to replication stress induced by nucleoside analog gemcitabine (Arlander et al., 2003; Bull et al., 2004) .
We therefore examined in this study whether the prototypical Hsp90 inhibitor GM functions as a G 2 abrogator in leukemia cell lines pretreated with antitumor agents. GM released low-dose doxorubicintreated Jurkat cells from G 2 arrest into G 1 phase. This release from G 2 arrest coincided with the tendency to undergo apoptosis instead of doxorubicin-induced necrosis.
Results

Treatment with geldanamycin depleted Chk1 protein
We performed western blot analysis for cell cycle-related and Hsp90 client proteins after 24 h of treatment with 100 nM doxorubicin, ara-C or GM in ML-1 and Jurkat cells (Figure 1 ). GM dramatically reduced the amount of Chk1 in addition to Raf and Akt in both cell lines. Cdc2 amount was also reduced in these cell lines after GM treatment. Furthermore, especially in ML-1 cells, considerable portion of the Rb protein became hypophosphorylated, which corresponds well with the previous report that GM induces G 1 arrest through the depletion of cyclin D and the resultant Rb hypophosphorylation (Srethapakdi et al., 2000) . Induction of p21 was apparent only in ML-1 cells after doxorubicin treatment (Figure 1 ).
GM abrogated DNA damage-induced G 2 arrest in Jurkat cells Because GM induced considerable loss of Chk1, we examined whether or not it acts as a G 2 abrogator. We first treated Jurkat cells with 50 nM doxorubicin for 24 h, which trapped most of the cells in late-S to G 2 position with almost complete loss of G 1 population. Then, we added 100 nM GM and monitored their cell cycle distribution. As shown in Figure 2a , G 2 -arrested Jurkat cells began to move to the G 1 position between 12 and 18 h after the addition of GM. Without GM, most of the doxorubicin-treated Jurkat cells stayed at G 2 phase for further 24 h. Subsequent addition of 200 nM nocodazole 12 h later, which trapped cycling cells at M phase, clearly suppressed the appearance of G 1 peak even after 24 h of incubation with GM. GM released HL-60 cells from doxorubicin-induced G 2 arrest essentially in the same way as Jurkat cells (data not shown).
Appearance of phosphorylated upper bands of Cdc25C, Myt 1 and Bcl-2 are hallmarks of the presence of mitotic cells (Sanchez et al., 1997; Ling et al., 1998) . Although nocodazole treatment for 12 h gave rise to the retarded upper bands of Cdc25C, Myt 1 and Bcl-2 in rapidly growing Jurkat cells, pre-and simultaneous treatment with 50 nM doxorubicin completely eliminated their upper retardation. Addition of 100 nM GM restored upper shift of Cdc25C, Myt 1 and Bcl-2 in doxorubicin-pretreated Jurkat cells, which confirmed the release from G 2 arrest and entrapment at mitosis by nocodazole (Figure 2c ). Simultaneous count of mitotic cell percentages confirmed the release from doxorubicininduced G 2 arrest by GM in Jurkat cells. We then examined the states of Chk1 in Jurkat cells treated with mock, 50 nM doxorubicin for 48 h, 100 nM GM for 24 h or with the combination of them, that is, in the last condition GM was added after 24 h of treatment with doxorubicin. GM depleted Chk1 more efficiently in Jurkat cells pretreated with doxorubicin than nontreated ones, which correlated well with the override of DNA damage-induced G 2 arrest (Figure 2d ). Time course analysis confirmed that GM reduced Chk1 level only gradually in doxorubicin-treated Jurkat cells, which is in good accordance with the relatively long interval between the addition of GM and release from the G 2 arrest (Figure 2e ). These results, which were confirmed essentially in the same condition at least three times, clearly showed that GM gradually releases Jurkat cells from the DNA-damage G 2 checkpoint.
GM abrogated decatenation-induced G 2 arrest in Jurkat cells Because GM depleted Chk1 and thus abrogated DNA damage-induced G 2 checkpoint, we next examined whether the agent also releases Jurkat cells from the decatenation-induced G 2 checkpoint. Treatment with 1.2 mM of ICRF-193 for 24 h almost completely trapped Jurkat cells at G2 phase essentially without G 1 population. Raf Figure 1 GM selectively depleted Raf, Akt1, Chk1 and Cdc2 in ML-1 and Jurkat cells. ML-1 and Jurkat cells were mock-treated (control) or treated with 100 nM doxorubicin, 100 nM GM or 100 nM ara-C for 24 h. Cell lysates were prepared, and equal amounts of these were separated and immunoblotted for Rb, Raf, Akt1, Chk1, Chk2, Cdc2, cyclin B1, PCNA, Bcl-2 and p21.
Addition of GM started to release Jurkat cells from decatenation-induced G 2 arrest into G 1 phase in 14 h (Figure 3a) . Addition of 200 nM nocodazole 12 h later clearly suppressed the appearance of G 1 peak even after 21 h of incubation with GM. GM contrasted with caffeine in abrogating ICRF-193-induced G 2 arrest more efficiently than doxorubicin-induced one (Figure 3b ). Furthermore, western blot analysis confirmed restoration of upperretarded M phase-specific bands of Cdc25C, Myt 1 and Bcl-2 by GM in ICRF-193-treated Jurkat cells (Figure 3c ). These results clearly showed that GM gradually releases Jurkat cells from the decatenation G 2 checkpoint. Western blot analysis against phosphoSer345 Chk1 clearly demonstrated that not only doxorubicin but also ICRF-193 activates Chk1. Indeed, ICRF-193 induced more intense phosphorylation of Chk1 at Ser345 than doxorubicin, and the Chk1 phosphorylation was apparently decreased by the treatment with GM ( Figure 3d ).
ML-1 cells with functional p53 were resistant to GM-induced G 2 abrogation In contrast to Jurkat and HL-60 cells lacking functional p53, ML-1 cells were arrested not only at G 2 but also at G 1 phases after 50 nM doxorubicin treatment (Figure 4a ). Therefore, cell cycle analysis by flow cytometry was not suitable for the estimation of G 2 abrogation by GM. Direct count of mitotic cell percentage showed that about 2.3% of rapidly growing ML-1 cells were mitotic. Total 48 h of pre-and simultaneous treatment with 50 nM doxorubicin reduced nocodazole-trapped cell percentage from 8.7 to 1.3%. Addition of 100 nM GM failed to increase mitotic cell percentage of doxorubicin-treated ML-1 cells (0.3% of mitotic cells, Figure 4b ). Therefore, ML-1 cells expressing wild-type p53, were resistant to G 2 checkpoint abrogation by GM in spite of Chk1 depletion. The preservation of G 2 arrest might be explained by p21 induction. Furthermore, addition of GM had little effects if any on the apoptotic cell percentage of doxorubicintreated ML-1 cells. Confocal microscopy confirmed nuclear import of cyclin B1 after the addition of GM in doxorubicin-treated HeLa cells (Figure 5c ). After 24 h, considerable portion of them entered mitosis with much larger amount of cyclin B1 than normal mitotic HeLa cells. Therefore, GM has two independent effects on the behavior of doxorubicin-pretreated HeLa cells, those are, release from the G 2 arrest and the following mitotic entrapment.
GM released HeLa cells from G
To inquire why HeLa but not Jurkat cells entrapped at the mitotic phase after going over the G 2 arrest, we examined the activation state of Plk1, an important regulator of M-phase progression ( Figure 5d ). Although addition of GM reduced not only total but also Thr210-phosphorylated Plk1 levels in HeLa cells pretreated with doxorubicin, GM rather increased the phosphorylated Plk1 level in Jurkat cells. Therefore, preserved Plk1 activity in spite of the decreased protein level in Jurkat cells may enable the completion of mitosis.
Addition of geldanamycin converted doxorubicin-induced necrosis to apoptosis in Jurkat cells
We previously showed that treatment with 50 nM doxorubicin for 48 h induced necrosis in most Jurkat cells without apparent apoptosis (Sugimoto et al., 2002) . In this study, addition of 100 nM GM at 24 h made more than 40% of doxorubicin-treated Jurkat cells TUNEL positive ( Figure 6a ). Treatment with 100 nM GM alone for 24 h induced few, if any, Jurkat cells TUNELpositive. Therefore, not GM per se but addition of GM to 50 nM doxorubicin-treated Jurkat cells induced TUNEL-positive apoptosis. Treatment with 50 nM doxorubicin for 48 h enhanced intracellular reactive oxygen species (ROS) formation in Jurkat cells, but reduction of mitochondrial membrane potential (DC m ) was absent. In contrast, addition of 100 nM GM at 24 h generated ROS-increased, DC m -decreased apoptotic cell population in about 40% of doxorubicin-pretreated Jurkat cells (Figure 6b ). Although reduction of DC m is not sufficient for commitment to apoptosis (Chen et al., 1998 ), combination of increase ROS level and decreased DC m is a hallmark of apoptosis. Therefore, flow cytometric ROS/DC m analysis also showed that GM converts low-dose doxorubicin-induced necrosis into apoptosis in Jurkat cells. Although Hsp90 inhibition has been reported to facilitate apoptosis by blocking NF-kB activation (Lewis et al., 2000; Broemer et al., 2004) , simultaneous treatment with GM rather enhanced NF-kB nuclear translocation in 50 nM doxorubicintreated Jurkat cells (Figure 6c) . Therefore, at least in Jurkat cells, facilitation of apoptosis by delayed addition of GM cannot be explained by NF-kB inhibition.
Addition of geldanamycin suppressed low-dose doxorubicin-treated cell survival To underline the biological significance and the clinical relevance of these results, we carried out the colony assay using Jurkat and HL-60 cells treated with 50 nM doxorubicin for 48 h in the presence or absence of 100 nM GM during the last 24 h. As controls, rapidly growing and GM-treated Jurkat and HL-60 cells were also plated. Surviving colony numbers of doxorubicinpretreated Jurkat cells decreased to almost 0% in the presence of GM, although treatment with GM alone reduced surviving colony number at most to 40% of rapidly growing Jurkat cells (Table 1) . In case of HL-60 cells, although the reduction of a surviving colony number by 100 nM GM alone was at most 67%, subsequent addition of GM dramatically reduced the surviving colony number of doxorubicin-treated HL-60 cells to 2-3% of that treated by doxorubicin alone. 
Almost no colonies were detected after ICRF-193 plus subsequent GM treatment in both cell lines. These results were confirmed in three independent series of experiments.
Discussion
In this study, we have shown that GM, a representative Hsp90 inhibitor, releases Jurkat and HL-60 cells from the doxorubicin-induced G 2 arrest in accordance with the Chk1 depletion. Although caffeine and UCN-01 usually abrogate doxorubicin-induced G 2 arrest in a few hours (Powell et al., 1995; Yao et al., 1996; Sugimoto et al., 2000) , it took more than 12 h to override the G 2 arrest by GM, which corresponds to a rather lengthy process of Chk1 depletion by Hsp90 inhibition. These observations are compatible with the hypothesis that reduction of Chk1 level may play a central role in G 2 abrogation by GM. Hsp90 is, however, responsible for the integrity of various client proteins. For example, interaction with Hsp90 is shown to be necessary for the activity of Wee1, an inhibitory regulator of mitotic entry, in fission yeast (Aligue et al., 1994) , although we confirmed that Wee1 level remained constant even after the addition of GM in Jurkat cells (data, not shown). Therefore, G 2 abrogation by GM may not be solely attributed to Chk1 depletion. Involvement of Chk1 in the decatenation checkpoint mechanism had been ruled out because of the lack of its activation after 2 h of incubation with ICRF-193 in a previous report (Deming et al., 2001) . However, treatment with 1.2 mM of ICRF-193 for 24 h clearly induced Chk1 phosphorylation at Ser345 in Jurkat cells, whose extent was much stronger than that induced by 50 nM doxorubicin. Furthermore, addition of GM attenuated the phosphorylation of Chk1 and abrogated the decatenation-induced G 2 arrest. These results indicate that both DNA-damage and decatenation checkpoints should induce G 2 arrest through a common pathway involving Chk1. Jurkat and HL-60 cells were treated with 50 nM doxorubicin or 2 mM ICRF-193 for 24 h, then split into three, and incubated for further 24 h in the presence or absence of 100 nM geldanamycin, then cell suspension containing 1 Â 10 4 cells was plated. As controls, nontreated Jurkat and HL-60 cells were incubated without or with 100 nM geldanamycin for 24 h and plated at 100 cells per plate. Each number was the mean value of 3 actual colony numbers of identical treatment condition after 20 days of incubation.
Geldanamycin-induced Chk1 depletion abrogates G 2 arrest K Sugimoto et al GM apparently failed to abrogate G 2 arrest in ML-1 cells expressing wild-type p53. As previously reported in p53-positive cells after g-radiation (Bunz et al., 1998) , p21 should directly block the cyclin B1-Cdc2 activity even after the depletion of Chk1 in ML-1 cells. The G 2 checkpoint of ML-1 cells should thus consist of p53-dependent and p53-independent pathways (Passalaris et al., 1999) , and GM abrogates only the latter Geldanamycin-induced Chk1 depletion abrogates G 2 arrest K Sugimoto et al pathway(s). In contrast, intra-S phase arrest elicited by cytarabine or gemcitabine seems to be dependent almost solely on Chk1 even in ML-1 cells, and therefore readily abrogated by GM (Arlander et al., 2003; Mesa et al., 2005) . In case of HeLa cells, although GM abrogated doxorubicin-induced G 2 arrest, they were trapped at M phase after the G 2 override. Confocal microscopy showed that GM-arrested mitotic HeLa cells contain much larger amount of cyclin B1 than the normal mitotic counterpart. Degradation of cyclin B1 is necessary for the exit from metaphase, and this process is mainly regulated by Plk1 (King et al., 1995; Descombbes and Nigg, 1998) . Recently, Plk1 has been shown to be an Hsp-90 client (de Ca´rcer, 2004) , and treatment with GM indeed reduced the total Plk1 level both in Jurkat and HeLa cells. However, GM rather increased phosphorylated Plk1 at Thr210 in doxorubicin-pretreated Jurkat cells although apparently reduced the phosphorylated Plk1 in HeLa cells. This difference may explain the GM-induced mitotic arrest solely in HeLa cells. In this study, we showed that addition of GM converted doxorubicin-induced necrosis into apoptosis in Jurkat and HL-60 cells. Colony assay confirmed that GM intensifies the cytotoxic effects of doxorubicin and ICRF-193, although GM has a weak cytotoxic effect as a single agent. Addition of GM, however, failed to enhance the cytotoxicity of doxorubicin against ML-1 cells, although GM or its derivatives has been shown to sensitize ML-1 cells to cytarabine and gemcitabine (Arlander et al., 2003; Mesa et al., 2005) . The different cytotoxic effects of additional GM in doxorubicintreated Jurkat and ML-1 cells seem to correlate with the abrogation and persistence of G 2 arrest, respectively. Even in ML-1 cells, override of intra-S phase checkpoint Geldanamycin-induced Chk1 depletion abrogates G 2 arrest K Sugimoto et al by GM leads to the enhancement of the cytotoxic activity of cytarabine and gemcitabine. These observations once more confirm the idea that abrogation of a major checkpoint response should be essential for the sensitization of various chemotherapeutic agents by GM. Although depletion of various Hsp90-client Geldanamycin-induced Chk1 depletion abrogates G 2 arrest K Sugimoto et al proteins including Akt1 may enhance cytotoxic effects of doxorubicin and ICRF-193, abrogation of G 2 checkpoint by GM should play a central role in sensitizing p53-negative leukemia cells to DNA-damaging and decatenation-blocking agents.
Materials and methods
Cell culture and drug treatment Jurkat, HL-60 and ML-1 human leukemia cell lines were maintained in RPMI 1640 (Sigma, St Louis, MO, USA)
supplemented with 10% fetal calf serum (FCS), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin. The cells were split to keep cell density at 3 Â 10 5 to 1 Â 10 6 cells per ml. HeLa human cervical cancer cell line was maintained in Dulbecco's modified Eagle's medium (Sigma) with 10% FCS, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. Logarithmically growing cells were treated with GM and antitumor drugs at indicated concentrations for a described period. GM, doxorubicin, ara-C (cytosine b-D-arabinofuranoside), etoposide and caffeine were purchased from Sigma, and ICRF-193 from Zenyaku kougyo (Tokyo, Japan). To trap cells at M phase, we used 200 nM nocodazole (Sigma) for indicated period. (a) were dual-stained with DiOC 6 and dihydroethidium to evaluate the change of DC m and reactive oxygen species (ROS) generation. GM reduced DC m , and 50 nM doxorubicin increased ROS generation. Combination of them generated a Jurkat cell population with reduced DC m and increased ROS, which corresponds to apoptotic cell population. (c) Confocal laser scanning microscopy determined cellular localization of NF-kB in Jurkat cells mock-treated (control), or treated with 50 nM doxorubicin for 24 h, with 100 nM GM for 24 h, or with both. Photographs of the same fields were obtained with optical filters specific for green and far-red lights (NF-kB and DNA signals, respectively).
Western blot analysis
Harvested cells were washed once with phosphate-buffered saline (PBS) and suspended in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol (DTT), 1% NP-40, 2% Complete Mini, EDTA-free (Roche Applied Science, Basel, Switzerland)). The suspension was kept on ice for 20 min, and centrifuged at 13 000 g for 10 min at 4 1C. The supernatant was recovered as total cell lysate and 10 mg of the aliquot was separated on a 7.5% polyacrylamide gel. Immunoblotting was performed using 1:2000 dilution of the indicated antibodies described below. We used mouse monoclonal antibodies against Rb, Chk1, Cdc2, cyclin B1, PCNA, p21 (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Bcl-2 (DAKO, Glastrup, Denmark), rabbit polyclonal antibodies against Chk2, Cdc25C (Santa Cruz Biotechnology) and Plk1 phosphorylated (Thr210; BioLegend, San Diego, CA, USA), and a rabbit monoclonal antibody against phospho-Chk1 (Ser345; Cell Signaling Technology, Danvers, MA, USA). As a second antibody, alkaline phosphatase-conjugated anti-mouse or antirabbit IgG antibody (ProMega, Madison, WI, USA) was used at the dilution of 1:5000.
Flow cytometric cell cycle analysis/TUNEL assay In brief, 1 Â 10 6 cells were harvested by centrifugation for 8 min at room temperature at 400 g, washed once with phosphatebuffered saline (PBS) and then fixed in 1% formaldehyde in PBS (pH 7.4) for 15 min on ice. After washing in PBS, cells were resuspended in 70% cold (À20 1C) ethanol and stored at À20 1C for 8 h. After rehydration in PBS, cells were resuspended in 50 ml of a cacodylate buffer containing 0.2 M potassium cacodylate, 25 mM Tris-HCl (pH 6.6), 2.5 mM CoCl 2 , 0.25 mg ml À1 bovine serum albumin, 5 units of terminal deoxynucleotidyl transferase and 0.5 nmol biotin-dUTP (all reagents were purchased from Boehringer Mannheim, Indianapolis, IN, USA). The cells were incubated in this solution at 37 1C for 30 min; rinsed in PBS; resuspended in 100 ml of a solution containing 4 Â concentrated saline-sodium citrate buffer, 2.5 mg ml À1 fluoresceinated avidin (Boehringer Mannheim), 0.1% Triton X-100 and 5% (w/v) nonfat dry milk; and incubated in this solution for 30 min at room temperature in the dark. The cells were then rinsed in PBS containing 0.1% Triton X-100, resuspended in 1 ml of PBS containing 5 mg ml À1 propidium iodide (PI) and 200 mg ml À1 RNase A (both from Sigma) and analysed by a CYTRON ABSOLUTE flow cytometer (Ortho, Raritan, NJ, USA), as previously described (Sugimoto et al., 1998) .
Flow cytometric reactive oxygen species production/ mitochondrial transmembrane potential analysis Changes in mitochondrial transmembrane potential (DC m ) were evaluated by staining with 1 nM 3,3 0 -dihexyloxacarbocyanine iodide (DiOC 6 [3]) (Molecular Probes, Eugene, OR, USA). ROS production was determined by staining with 2 mM dihydroethidium (DHE; Molecular Probes). DHE is a cell permeable dye, which becomes fluorescent when oxidized by either H 2 O 2 or superoxide in the cell. Cells were washed once with PBS and incubated with the dyes in PBS for 15 min at 37 1C and subsequently washed twice with cold PBS before analysis using a CYTRON ABSOLUTE flow cytometer.
Direct count of mitotic cell percentage
In brief, 1 Â 10 5 cells were centrifuged directly onto a slide glass (400 g, 8 min at room temperature) using SC-2 centrifugal cell collector (Tomy, Tokyo, Japan), air dried briefly and then stained according to the Wright-Giemsa method. A total of 1000 cells were microscopically examined for each treatment condition.
Confocal laser microscopy
Jurkat cells were directly attached to a poly-L-lysine-coated cover glass by centrifugation at 400 g, fixed in 1% paraformaldehyde in PBS (pH 7.4) for 15 min at room temperature and permeabilized with 0.1% Triton X-100 in PBS. The cover glass was incubated with a 1:50 dilution of anti-NF-kB (p65) mouse monoclonal antibody (Santa Cruz Biotechnology) in PBS with 3% FCS for 1.5 h, washed with0.1% Triton X-100 in PBS and stained with a 1:100 dilution of FITC-conjugated goat-anti-mouse IgG. DNA was counterstained with a 1:1500 dilution of TOTO-3 iodide (642/660) in PBS for 10 min. The stained side of the cover glass was stuck to a slide glass with FluoroGuard Antifade Reagent (Bio-Rad, Hercules, CA, USA) and sealed with nail polish. The slides were viewed and photographed using a Zeiss LSM510 confocal laser scanning microscopy (Carl Zeiss, Jena, Germany). HeLa cells grown in 35 mm Glass Bottom Culture Dishes (MatTek Corporation, Ashland, MA, USA) were fixed with methanol/ acetone (7:3) for 15 min at À20 1C, dried and re-hydrated in PBS. Cells were immunostained essentially the same procedure for cover glass-fixed Jurkat cells except for using anticyclin B1 mouse monoclonal antibody (Santa Cruz Biotechnology) as primary antibody.
Clonal cell culture Methylcellulose cell culture was carried out in a 35-mm suspension culture dish (Nalge Nunc, Rochester, NY, USA) using Methocult H4230 (Stem Cell Technologies, Vancouver, BC, Canada) essentially as described previously (Sugimoto et al., 2002) . Rapidly growing Jurkat and HL-60 cells were treated with 50 nM doxorubicin or with 1.2 mM of ICRF-193 for 24 h, and further incubated in the presence or absence of 100 nM GM for additional 24 h. Then living cell numbers were counted by trypan blue exclusion test, and 1 Â 10 4 cells were plated for each condition as triplicate. As controls, nontreated Jurkat and HL-60 cells were incubated without or with 100 nM GM for 24 h and plated at 100 cells per plate. Colony numbers were assessed after 20 days of incubation at 37 1C in a humidified atmosphere with 5% CO 2 . Colonies were defined as aggregates of more than 50 cells.
